Phreesia, Inc. (NYSE:PHR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Phreesia, Inc. (NYSE:PHR) have received a consensus recommendation of “Moderate Buy” from the nineteen analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $29.1176.

Several analysts recently commented on the company. Barclays dropped their target price on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of Phreesia in a report on Monday, December 8th. JPMorgan Chase & Co. lowered their price objective on Phreesia from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, December 9th. Finally, Mizuho set a $22.00 target price on shares of Phreesia in a report on Wednesday, February 4th.

Phreesia Price Performance

Shares of PHR opened at $11.01 on Tuesday. The business’s 50-day moving average is $13.58 and its two-hundred day moving average is $18.91. The company has a market capitalization of $663.49 million, a P/E ratio of -110.04 and a beta of 0.67. Phreesia has a fifty-two week low of $10.75 and a fifty-two week high of $32.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44.

Insider Activity at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 4,687 shares of Phreesia stock in a transaction on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $76,679.32. Following the completion of the transaction, the chief financial officer owned 150,569 shares of the company’s stock, valued at approximately $2,463,308.84. The trade was a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Evan Roberts sold 6,268 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the completion of the transaction, the insider owned 826,554 shares of the company’s stock, valued at approximately $13,522,423.44. This trade represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 60,766 shares of company stock valued at $1,013,817 in the last quarter. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phreesia

A number of large investors have recently bought and sold shares of the business. Raymond James Financial Inc. grew its holdings in Phreesia by 2.7% in the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after purchasing an additional 375 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Phreesia by 2.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock worth $569,000 after buying an additional 540 shares during the period. Diversified Trust Co raised its stake in shares of Phreesia by 1.7% during the 3rd quarter. Diversified Trust Co now owns 45,822 shares of the company’s stock worth $1,078,000 after buying an additional 780 shares during the period. Alliancebernstein L.P. lifted its position in shares of Phreesia by 1.3% during the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after buying an additional 812 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Phreesia by 9.2% during the 2nd quarter. Bank of Montreal Can now owns 11,277 shares of the company’s stock valued at $321,000 after buying an additional 950 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.